anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Schizophrenia is a debilitating psychiatric disorder that can significantly affect a patient's quality of life and lead to permanent brain damage. Although medical research has identified certain genetic risk factors, the specific pathogenesis of the disorder remains unclear. Despite the prevalence of research employing magnetic resonance imaging, few studies have focused on the gene level and gene expression profile involving a large number of screened genes. However, the high dimensionality of genetic data presents a great challenge to accurately modeling the data. To tackle the current challenges, this study presents a novel feature selection strategy that utilizes heuristic feature fusion and a multi-objective optimization genetic algorithm. The goal is to improve classification performance and identify the key gene subset for schizophrenia diagnostics. Traditional gene screening techniques are inadequate for accurately determining the precise number of key genes associated with schizophrenia. Our innovative approach integrates a filter-based feature selection method to reduce data dimensionality and a multi-objective optimization genetic algorithm for improved classification tasks. By combining the filtering and wrapper methods, our strategy leverages their respective strengths in a deliberate manner, leading to superior classification accuracy and a more efficient selection of relevant genes. This approach has demonstrated significant improvements in classification results across 11 out of 14 relevant datasets. The performance on the remaining three datasets is comparable to the existing methods. Furthermore, visual and enrichment analyses have confirmed the practicality of our proposed method as a promising tool for the early detection of schizophrenia.
Hepatitis B virus (HBV) infections affect approximately 296 million people around the world, and the prevalence of any past or present HBV infection during the years 2015-2018 was as high as 4.3%. Acute HBV infection often presents with nonspecific symptoms and is usually self-limited, but 5% of patients can have persistent infections leading to chronic HBV infection and the risk of turning into chronic HBV infection is significantly higher in babies with vertical transmission (95%). Patients with chronic HBV infection are usually asymptomatic, but 15 to 40% of chronic HBV carriers develop cirrhosis and/or hepatocellular carcinoma. In addition to liver-related disorders, HBV is also associated with several extrahepatic complications, including glomerulonephritis, cryoglobulinemia, neurologic disorders, psychological manifestations, polyarthritis, and dermatologic disorders. Making the diagnosis of HBV can be challenging since patients with chronic infections can remain symptom-free for decades before developing cirrhosis or hepatocellular carcinoma, and patients with acute HBV infection may have only mild, nonspecific symptoms. Therefore, understanding how this virus causes extrahepatic complications can help clinicians consider this possibility in patients with diverse symptom presentations. The pathophysiology of these extrahepatic disorders likely involves immune-related tissue injury following immune complex formation and inflammatory cascades. In some cases, direct viral infection of extrahepatic tissue may cause a clinical syndrome. Currently, the American Association for the Study of Liver Diseases recommends treatment of chronic HBV infections with interferon therapy and/or nucleos(t)ide analogs, and this treatment has been reported to improve some extrahepatic disorders in some patients with chronic HBV infection. These extrahepatic complications have a significant role in disease outcomes and increase medical costs, morbidity, and mortality. Therefore, understanding the frequency and pathogenesis of these extrahepatic complications provides important information for both specialists and nonspecialists and may help clinicians identify patients at an earlier stage of their infection.
BACKGROUND & OBJECTIVE: Psychologically informed care has been proposed to improve treatment outcomes for chronic pain and aligns with a person-centered approach. Yet implementation lags behind, and studies suggest that a lack of competency leads to poor results. It is unclear what training clinicians require to deliver this care. We examine how we might improve psychologically informed care guided by the needs of the patient and in congruence with the scientific literature with a particular focus on how competencies might be upgraded and implementation enhanced.
METHODS: We selectively review the literature for psychologically informed care for pain. The patient's view on what is needed is contrasted with the competencies necessary to meet these needs and how treatment should be evaluated.
RESULTS: Patient needs and corresponding competencies are delineated. A number of multi-professional skills and competencies are required to provide psychologically informed care. Single-subject methodologies can determine whether the care has the desired effect for the individual patient and facilitate effectiveness. We argue that becoming a competent "pain clinician" requires a new approach to education that transcends current professional boundaries.
CONCLUSIONS: Providing person-centered care guided by the needs of the patient and in line with the scientific literature shows great potential but requires multiple competencies. We propose that training the pain clinician of the future should focus on psychologically informed care and the competencies required to meet the individual's needs. Single-subject methodology allows for continual evaluation of this care.
BACKGROUND AND AIMS: Women aged 55 to 59 years have a similar prevalence rate and number needed to screen for colorectal adenomas as men at a 10-year younger age. The aim of this study was to determine sex-specific differences in colorectal cancer mortality and estimate the association with adenomas at screening colonoscopy.
METHODS: This retrospective study analyzed 323,139 individuals who underwent colonoscopy within a national colorectal cancer screening program in Austria between January 2007 and December 2020.
RESULTS: Median patient age was 60 years (interquartile range, 54-67), and the sex distribution in all age groups was nearly identical. Men had significantly higher odds of having an adenoma or serrated polyp, low-risk polyp, high-risk polyp, or colorectal cancer detected at colonoscopy than women (odds ratio [OR] 1.83; 95% confidence interval [CI], 1.80-1.86; OR, 1.46; 95% CI, 1.44-1.49; OR, 1.74; 95% CI, 1.69-1.80; and OR, 1.87; 95% CI, 1.70-2.05, respectively). Strikingly, male sex, when compared with female sex, was associated with an almost 2-fold (hazard ratio, 1.67; 95% CI, 1.05-2.67) increased risk to die from colorectal cancer when an adenoma or serrated polyp was found at the screening colonoscopy and a 4-fold (hazard ratio, 4.14; 95% CI, 2.72-6.3) increased risk when a high-risk polyp was found at the screening colonoscopy. The cumulative incidence for death of colorectal cancer for 60-year-old individuals was 8.5-fold higher in men as compared with women. Markedly, this sex gap narrowed with increasing age, whereas the difference in deaths of other causes remained similar in all age groups.
CONCLUSIONS: Our findings strengthen the necessity of sex-specific screening recommendations. Importantly, further prospective studies should focus on sex differences in tumor biology to propose personalized surveillance guidelines.
1438790 Foil-sealed, impregnated carriers for hand care W HURKA 10 Aug 1973 [15 Feb 1973] 38005/73 Headings A5E and ASB A carrier, air-tightly and moisture-tightly sealed in foil, is impregnated with a composition for the protection of the hands, which composition contains a film-forming agent which forms a protective film on the skin, together with one or more active substances for the disinfection, protection or care of the skin. The carrier may be a towel based on paper, plastics material or textile material, or a sponge or pad of wadding. The foil preferably is an optionally coated aluminium foil. The following substances are preferably used as film-forming agents: 1) Macromolecular filmforming agents, a) natural mucilages: gums, alginates, dextrans, b) semi-synthetic macromolecules: methyl and ethylcellulose esters or ethers, for example ethylhydroxyethylcellulose, methylcellulose, carboxymethylcellulose, c) entirely synthetic macromolecules. polyvinyl alcohol, polyvinylpyrrolidone, and polyacrylic acids, 2) Fats, oils waxes: for example wool fat alcohol, cetyl alcohol, stearates, petroleum jelly, paraffin oil, polyethylene glyools, 3) Silicone oil. Specified disinfectants are listed amphoteric substances, quaternary ammonium compounds, chlorohexidine salts, aldehydes, phenol derivatives and hexachlorophene. Active ingredients for the protection or care of the skin are:- a) Sun protection media: for example, p-aminobenzoates, salicylates, anthranyl salts, zinc oxide, b) Active substances protecting against radiation for example: brominated oleic acid, c) Substances protectng against dust: stearic acid, waxes, d) Substances protecting against absorption of chromium, lead or other heavy metals; e.g. complexing agents, hydroquinones, e) Substances for the care of skin; for example refatting and superfatting agents, glycerine partial fatty acid esters, glycerine, a triglyceride of saturated vegetable fatty acid of medium chain length, an ethoxylated fatty acid monoglyceride ester, a composition of saturated triglycerides of natural fatty acids, lanolin; f) Substances assisting wound healing and tissue regeneration: allantoin, vitamin A, fish-liver oil, vitamin C.
INTRODUCTION: The direct factor Xa inhibitor apixaban is partially eliminated by the kidneys but is still prescribed at fixed doses without therapeutic drug monitoring across varying levels of renal function. If apixaban accumulates due to renal impairment, this may translate into safety concerns, e.g. the risk for bleeding. The purpose of this study was to measure apixaban trough concentrations in patients with different stages of renal function/renal impairment.
METHODS: Apixaban trough concentrations were measured using LC-MS/MS in patients with atrial fibrillation, having normal renal function (apixaban 5 mg BID, n=39), moderate renal impairment (apixaban 5 mg BID, n=40) and severe renal impairment (apixaban 2.5 mg BID, n=6). The median (min-max) relative eGFR values were 84.8 (71.7-111.4), 51.4 (31.3-67.2) and 23.0 (21.9-28.4) mL/min/1.73 m², in the three groups, respectively.
RESULTS: Patients with moderate renal impairment had significantly higher apixaban trough concentrations than patients with normal renal function. The median (min-max) trough concentrations were 59.8 ng/mL (15.5-170.9) for normal renal function, 128.9 ng/mL (41.4-295.4) for moderate renal impairment and 81.7 ng/mL (61.8-109.0) for severe renal impairment. The trough concentrations correlated significantly with renal function measured as relative/absolute eGFR creatinine/cystatin C.
CONCLUSIONS: The standard dosing regimen of 5 mg apixaban BID renders exposure that is roughly twice as high in patients with moderately reduced renal function compared to patients with normal renal function. We suggest that patients with moderately reduced renal function ought to be monitored. Possibly, a dose reduction may be considered to achieve similar exposure as in patients with normal renal function.
SY-4798 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached. In dose-expansion phase, preliminary anti-tumor activity will be assessed in FGF19+ advanced tumor.
The invention provides an application of sabaforine in preparing a drug-resistant osteosarcoma drug, belonging to the field of medicines. The invention provides application of sabaforine in preparing a drug resistant osteosarcoma drug, wherein a cell line of the drug resistant osteosarcoma comprises U2OS/MTX300. The arenobufagin has obvious effects of inhibiting cell proliferation and inducing apoptosis on drug-resistant bone tumor cells. The lower concentration of sabaforine (5. Mu. Mol/L) can play a role in inhibiting U2OS by high concentration of diosgenin (100. Mu. Mol/L). As a natural plant extracted medicine, the sabaforine has wide application prospect in the field of anti-tumor medicine treatment.
In man, following oral once-daily dosing over the range of 50 to 200 mg for 14 days, mean peak plasma concentrations (Cmax) of sertraline occurred between 4.5 to 8.4 hours post-dosing. The average terminal elimination half-life of plasma sertraline is about 26 hours. Based on this pharmacokinetic parameter, steady-state sertraline plasma levels should be achieved after approximately one week of once-daily dosing. Linear dose-proportional pharmacokinetics were demonstrated in a single dose study in which the Cmax and area under the plasma concentration time curve (AUC) of sertraline were proportional to dose over a range of 50 to 200 mg. Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation, compared to a single dose, of sertraline with repeated dosing over a 50 to 200 mg dose range. The single dose bioavailability of sertraline tablets is approximately equal to an equivalent dose of solution.

In a relative bioavailability study comparing the pharmacokinetics of 100 mg sertraline as the oral solution to a 100 mg sertraline tablet in 16 healthy adults, the solution to tablet ratio of geometric mean AUC and Cmax values were 114.8% and 120.6%, respectively. 90% confidence intervals (CI) were within the range of 80–125% with the exception of the upper 90% CI limit for Cmax which was 126.5%.

The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food.
A method for correcting of anterior upper extrapleural toracoplastics comprises the dissection of soft tissues during operative access along the clavicle to the axillary area of the muscle bundles without dissection and removal of the long thoracic nerve and the lateral thoracic vein, followed by resection of the ribs. Operational service performed in the patient lying on its back with a hand passing perpendicular to the axis of the body (spine, sternum). Under visual control primarily engaged in the subclavian area of resection of the first rib. The paravertebral resection of required number of ribs to be removed is performed from the axillary area in one plane without rotation, with the number of ribs to be removed, is determined after opening of second rib periosteum with finger examination of the residual cavity and complete release of rebirth fibrous arch of the residual cavity, which "stripes" on the ribs and fills the remaining cavity. Then the microirrigator is introduced into the cavity, and drainage - into soft tissues. The wound is sutured out with extracorporeal compression by special fashion rollers.
The invention provides a compound Chinese medicinal powder for treatment of chicken indigestion and a preparation method thereof. The powder consists of the following 5 drugs: perilla leaf, Cyperus rotundus, dried tangerine peel, dried ginger, and licorice. Effective components are extracted from the drugs respective according to certain technical method. The method is characterized by increasing the perilla leaf dose and reducing the toxicity to 1/1000 by certain preparation process. The whole compound is rigorous, the process is simple and reasonable, and the prepared powder is convenient to use and has a long period of validity. Thus, the prescription powder has better curative effect and wider indications, and realizes the purposes of safety, effective, stable and convenient use on chickens.
Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
Steatotic liver disease (SLD) is characterized by hepatic fat accumulation, potentially causing major consequences such as liver decompensation. Currently, we lack medications for the treatment of SLD. Therapeutic recommendations for patients include a hypocaloric diet, weight loss, and physical activity. In particular, the Mediterranean diet is frequently recommended. However, this diet might exacerbate intestinal problems in a subset of patients with coexisting small intestinal bacterial overgrowth (SIBO). Previous studies have reported that SIBO is more predominant in patients with fatty liver than in healthy individuals. Both our research and the findings of others have highlighted a challenge related to nutritional therapy in patients with fatty liver who also suffer from SIBO inasmuch as SIBO induces several phenomena (like bloating or abdominal pain) that can adversely affect patients' quality of life and might be exacerbated by the Mediterranean diet. This may lower their adherence to the intervention. As a solution, we suggest introducing additional diagnostics (e.g., breath test) in patients with SLD who complain of SIBO-like symptoms. The next step is to modify their diets temporarily starting with several weeks of "elimination and sanitation." This would involve restricting products rich in fermentable sugars and polyols, while simultaneously treating the bacterial overgrowth. In summary, while the hypocaloric Mediterranean diet is beneficial for patients with fatty liver, those with coexisting SIBO may experience exacerbated symptoms. It is vital to consider additional diagnostics and dietary modifications for this subset of patients to address both liver and intestinal health concurrently.
Participants will first be provided with a brief overview of the science of breathing and benefits for autonomic regulation. Then, participants will receive specific practice instruction and guided breathing at a rhythm of 6 breaths/min (4-6 count) via auditory tones. Each participant will be encouraged to breathe as comfortably and effortlessly as possible, while keeping the lungs moving in accordance with the audio guidance. The accompanying training and daily instruction reminder will emphasize the importance of following the specific rhythm of breathing, without regard to thoughts or inner experience. A soft but firm tone of voice will be employed to minimize likelihood of relaxing effects, while maintaining similarity to the tone of voice used in the other conditions.
Each gram contains 100 mg of sodium sulfacetamide and 50 mg of colloidal sulfur in a vehicle consisting of: benzyl alcohol, cetyl alcohol, disodium EDTA, fragrance, glyceryl stearate (and) PEG-100 stearate, magnesium aluminum silicate, PEG-150 distearate, phenoxyethanol, polyethylene glycol 400, purified water, sodium lauryl sulfate, sodium thiosulfate, stearyl alcohol and xanthan gum.

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Sodium sulfacetamide is C 8H 9N 2NaO 3S·H 2O with molecular weight of 254.24. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is: 

Sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether.
A method for preserving the stability of a haemoglobin blood substitute comprising maintaining the haemoglobin blood substitute in an atmosphere substantially free of oxygen. It involves a method for producing a stable polymerised haemoglobin blood-substitute from blood. The method includes mixing blood with an anticoagulant to form a blood solution, washing the red blood cells in the blood solution and then separating the washed red blood cells from the white blood cells. This method also includes disrupting the red blood cells to release haemoglobin and form a haemoglobin solution, which is then treated by high performance liquid chromatography to form a haemoglobin eluate. The haemoglobin eluate is then deoxygenated, contacted with a first sulfhydryl compound to form an oxidation-stabilised deoxygenated haemoglobin solution, and mixed with a cross-linking agent to form a polymerisation reaction mixture, which is then polymerised. The polymerised haemoglobin solution is then diafiltered with a physiologic solution and with a sulfhydryl compound, whereby the polymerised haemoglobin solution is made physiologically acceptable, and whereby the sulfhydryl compound scavenges oxygen, to form a stable polymerised haemoglobin blood-substitute, which is then packaged and stored in an atmosphere substantially free of oxygen.
A facile approach is described to prepare monodisperse Fe3O4 and Co3O4 nanoparticles on chemically reduced graphene oxide (rGO) to form nanocomposites by low temperature solution route and MWI method, respectively. These processes are environmentally friendly and convenient compared with previously reported methods. The synthesized nanocomposites were characterized using x-ray diffraction spectroscopy (XRD), raman spectroscopy, scanning electron microscopy (SEM) measurements and UV/Vis absorption spectroscopy. XRD patterns revealed the high crystalline quality of the nanocomposites. SEM micrographs showed the morphology of the rGO nanosheets decorated by Co3O4 and Fe3O4 nanoparticles. UV/Vis study revealed the formation of Fe3O4/rGO and Co3O4/rGO nanocomposites with characteristics absorption maxima. Finally, preliminary results of using the Fe3O4/rGO and Co3O4/rGO composites for efficient killing of Human hepatocytes cancer (HepG2) cell are reported. Nanocomposites produced by MWI showed better anticancer activity and higher yield than that of low temperature solution route.
The antihypertensive effects of olmesartan medoxomil were evaluated in one randomized, double-blind clinical study in pediatric patients 1 to 16 years of age [see Clinical Studies (14.2)]. The pharmacokinetics of olmesartan medoxomil tablets were evaluated in pediatric patients 1 to 16 years of age [see Clinical Pharmacology (12.3)]. Olmesartan medoxomil was generally well tolerated in pediatric patients, and the adverse experience profile was similar to that described for adults.

Olmesartan medoxomil has not been shown to be effective for hypertension in children

< 6 years of age.

Use of olmesartan medoxomil in children <1 year of age is not recommended [see Warnings and Precautions (5.2)]. The renin-angiotensin-aldosterone system (RAAS) plays a critical role in kidney development. RAAS blockade has been shown to lead to abnormal kidney development in very young mice. Administering drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) can alter normal renal development.
NEW MATERIAL:Benzopyrone derivatives of formula I (R is halogen, cyano, carboxyl, etc.; n is 3,5,6). EXAMPLE:7-Bromo-1,2,3,9-tetrahydrocyclopenta[b][1]benzopyran-9-one. USE:Drug having antiallergic, anti-inflammatory and analgesic activities. PREPARATION:An acylated salicilic acid of formula II (R2 is halogen; R3 is lower alkyl) or its reactive derivative on the carboxyl group as 5-bromoacetylsalicilic acid and a compound of formula III as 1-pyrrolidinocyclopentene are stirred in an inert solvent as dichloromethane at room temperature for 3-5hr. After the solvent is distilled off, a basic aqueous solution as pyridine or acidic solution as hydrochloric acid is added to the residue and they are refluxed to give the compound of formula Ia.